Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants

Phase 2

Completed

Conditions: Wound Healing

Interventions: Drug: TolaSure Topical Gel
Drug: Topical Vehicle Gel

Registration Number: NCT04088357

Lead Sponsor: BioMendics, LLC

Brief Summary: TolaSure is a topical gel for the promotion of accelerated wound healing. This phase II study will primarily assess the efficacy of TolaSure when applied to skin wounds created by punch biopsy in healthy participants. Safety, cutaneous tolerability, wound pain control, and quality of healing will also be assessed. A total of 80 healthy volunteers, males and females ages 18 years or older, will be enrolled. Subjects will be monitored for safety and efficacy until wound closure (estimation about 8 weeks) following topical administration of TolaSure.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 72

Inclusion Criteria

Healthy Males and Females > 18 years of age
Health history review
Physical exam
Blood and urine clinical chemistries
Negative pregnancy test

Exclusion Criteria

Acute or chronic skin disorders (e.g. psoriasis);
Acne or dermatitis at the test site;
Prone to keloids or hypertrophic scarring;
Topical or systemic antibiotics within 4 weeks of study enrollment;
Subjects with known severe mental illness which, in the investigator's opinion, may prevent informed consent or interfere with the subject's ability to comply with study protocol procedures;
Diagnosed with Diabetes Type I/II or glucose results indicative of prediabetic condition;
Morbidly obese with a Body Mass Index (BMI) ≥ 40;
Surgery within the previous 3 months (except for minor cosmetic or dental procedures)
History of severe vitamin or mineral deficiency;
History of drug or alcohol abuse (as defined by the Investigator);
Smoking/Vaping;
HIV/AIDS;
Consistently taking steroids and/or non-steroidal anti-inflammatory drugs. Subjects may use NSAIDs on an as needed basis with no more than 7 days of consecutive use;
Cancer diagnosis in the last 5 years;
Currently receiving chemotherapy or radiation;
Women who are pregnant, nursing, or planning a pregnancy;
Hyper- or hypo-pigmentation, or tattoos in the area where they will place the test fields;
Symptoms of a clinically significant illness in the four weeks before treatment application that may influence the outcome of the study;
Treatment with any investigational agent within one month before treatment application for this trial;
Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits on schedule;
Other unspecified reasons that, in the opinion of the Investigator, make the subject unsuitable for enrollment.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
5 Percent TolaSure Topical Gel	TolaSure Topical Gel	5%(w/w) TolaSure Gel
Topical Vehicle Gel	Topical Vehicle Gel	Vehicle Gel

Primary Outcome Measures

Name	Time	Method
Accelerated Wound Closure	Day 1, 2, and 7, then weekly until closure (estimated 8 weeks)	Time-to-closure will be calculated by the number of days from biopsy to wound closure. Wound closure (changes in wound area (mm\^2) over time) will be determined by the digital imaging platform software with Principal Investigator confirmation.

Secondary Outcome Measures

Name	Time	Method
Percent Area Reduction after Four Weeks	Week 4	Wound area measurements (mm\^2) will be calculated at week 4 by using a digital imaging. A percent reduction in area at week 4 will be calculated by comparing the initial area of the biopsy at Day 1 to the week 4 biopsy area.
Wound Pain Control	Day 2 and 7, then weekly until wound closure (estimated 8 weeks)	Wound-related pain or discomfort will be assessed, using the Visual Analog Scale (VAS) for Pain, for each individual wound site as pain at rest followed by pain to touch. The VAS Pain is a continuous scale comprised of a horizontal line, 10 centimeters (100 mm) in length. Pain will be defined per the following scale: None - 0-4 mm; Mild - 5-44 mm: Moderate - 45-74; Severe - 75-100 mm
Quality of Healing	End of study (estimated 8 weeks)	Patient and Observer Scar Assessment Scale (POSAS) version 2.0 will be used to assess the quality of healing of each biopsy site at the end of the study once both wounds are closed.
Cutaneous Tolerability	Day 1, 2, and 7, then weekly until wound closure (estimated 8 weeks)	Cutaneous tolerability will include an evaluation of erythema and edema following the modified Draize scoring system. Draize scores will be recorded and changes from baseline Draize scores will be monitored over the course of the time frame. Draize Scoring System. Erythema: 0-No Erythema, 1-Slight Erythema, 2-Well Defined Erythema, 3- Moderate or Severe Erythema, 4- Severe Erythema or slight eschar formation. Edema: 0- No Edema, 1- Very Slight Edema(barely perceptible), 2-Slight Edema (well defined edges), 3-Moderate Edema (raised \>1mm), 4- Severe Edema (raised \>1mm and extending beyond the area of exposure)
Blood and Urine Chemistries	Screening, Day 2 and 7, then weekly until wound closure (estimated 8 weeks)	Absolute values and changes over time of clinical chemistries including; Absolute values and changes over time of clinical blood and urine chemistries including; Hematology and Coagulation, Coagulation, Serum Chemistry, and Urinalysis. Blood and urine analytes are measured on a per mL basis.